Data Insights

FPI-1434 by Fusion Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Triple-Negative Breast Cancer (TNBC)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Uveal Melanoma: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Uveal Melanoma

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Endometrial Cancer: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Endometrial Cancer

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Cervical Cancer: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Cervical Cancer

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Ovarian Cancer: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Ovarian Cancer

Data Insights

FPI-2059 by Fusion Pharmaceuticals for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Recurrent Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-2059 in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

FPI-2059 by Fusion Pharmaceuticals for Metastatic Prostate Cancer: Likelihood of Approval

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-2059 in Metastatic Prostate Cancer

Data Insights

FPI-2059 by Fusion Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-2059 in Metastatic Colorectal Cancer

Data Insights

FPI-2059 by Fusion Pharmaceuticals for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-2059 in Pancreatic Ductal Adenocarcinoma

Data Insights

FPI-2059 by Fusion Pharmaceuticals for Ewing Sarcoma: Likelihood of Approval

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-2059 in Ewing Sarcoma

Data Insights

FPI-2059 by Fusion Pharmaceuticals for Gastric Cancer: Likelihood of Approval

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-2059 in Gastric Cancer

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Ewing Sarcoma: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Ewing Sarcoma

Data Insights

FPI-2265 by Fusion Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-2265 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

FPI-2068 by Fusion Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

FPI-2068 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Data Insights

FPI-2068 by Fusion Pharmaceuticals for Solid Tumor: Likelihood of Approval

FPI-2068 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Data Insights

FPI-2068 by Fusion Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

FPI-2068 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Data Insights

FPI-2265 by Fusion Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...